Physician profile
Maureen Strobel
NPI 1093448854
$451.51
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.44 · 2023: $243 · 2024: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $119.33 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Novo Nordisk INC | $52.22 | 2024 | Ozempic, Rybelsus |
| Pfizer INC. | $48.81 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.69 | 2023-2024 | Synjardy, Jardiance, Tradjenta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.59 | 2023-2024 | Caplyta |
| Amgen INC. | $34.92 | 2024 | Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $29.68 | 2023 | Rexulti |
| Alkermes, INC. | $25.56 | 2024 | Aristada, Lybalvi |
| Dexcom, INC. | $20.01 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $19.46 | 2024 | Gvoke Hypopen |
| Organon LLC | $17.24 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Strobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.